



Programme



8TH ANNUAL MEETING
Online · 2024



8th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 27th – Saturday, Sept 28th, 2024

Sponsored by:



Invitation 8th Meeting - Online

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to invite you to the 8th annual EHTG meeting which will take place on the **27th and 28th of September 2024 – online!** Our lively programme includes selected hot and controversial topics, in depth debates, audience discussion including the opportunity to discuss challenging clinical cases. We also aim to utilise the event to further explore collaboration across our members.

Day 1 (Friday) will include plenary sessions, a debate on an area of current clinical equipoise and a keynote lecture on an emerging hot topic. On Day 2 (Saturday), there will be interactive working groups (WG), a Dragon's Den session where young scientists pitch their research ideas – organized by the yEHTG, and an update on chemoprevention in hereditary cancer. Furthermore, you will be able to present your most challenging cases and discuss them with an expert panel.

Please visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries. If you have any suggestions, please get in touch with any of the programme members.

We are excited to see you in September!

Sincerely yours

EHTG programme committee and board members



Content

Invitation	2
Organisation	4
Day 1 – Friday, September 27th	
Lynch syndrome	6
Fertility / Pregnancy	6
Guidance from patient organizations	7
Debate: Rectal cancer in 2024 – Organ preservation for everyone?	8
Desmoid disease	8
Keynote lecture	8
Day 2 – Saturday, September 28th	
Y-EHTG	10
4 parallel Working Groups Titel	10
Working Group 1	11
Working Group 2	12-13
Working Group 3	13-14
Working Group 4-	14-15
My most challenging/interesting case	15
Prevention Update	16
EHTG-N Nursing Group	16-17
Meeting summary and closing remarks	17
Faculty	18-25
Sponsors	26
Imprint	27

Organisation

Board Members:

Aysel Ahadova (Germany)
 Peter Bauerfeind (Switzerland)
 John Burn (United Kingdom)
 Mev Dominguez Valentin (Norway)
 Saskia Haupt (Germany)
 Kelly Kohut (United Kingdom)
 Florian Kühn (Germany)
 Fiona Laloo (United Kingdom)
 Laura Monje-Garcia (United Kingdom)
 Gabriela Möslein (Germany)
 Neil Ryan (United Kingdom)
 Julian Sampson (United Kingdom)
 Toni Seppälä (Finland)

Programme Committee:

Florian Kühn (Germany, Programme Director)
 Aysel Ahadova (Germany)
 Ann-Sofie Backman (Sweden)
 Richard Gallon (United Kingdom)
 Elizabeth Half (Israel)
 Neil Ryan (United Kingdom)
 Laura Thomas (United Kingdom)

Secretariat:

Gabriele Sponholz
gs007@ehtg.org
 +49-160-8459502
 D-65207 Wiesbaden (Germany)

Registration:

Only online via www.ehtg.org

Registration Fee:

See online via www.ehtg.org

Certification:

We have applied for certification by EACCME

Technical organisation online part:

Miaglossa GmbH, Köln
support@miaglossa.com



Notes



Scan the QR code or click the button to
sign up today

Click to Register

Scientific Programme

Day 1 – Friday, September 27th

12:55 **Welcome**
John Burn (United Kingdom)

13:00-14:15 **Lynch syndrome**
Chairs: Ingrid Winship (Australia)
Kevin Monahan (United Kingdom)

13:00-13:15 **Lynch syndrome - beyond the colon and the endometrium**
John Burn (United Kingdom)

13:15-13:30 **Dominantly inherited MSI cancers - an update of the PLSD**
Mev Dominguez-Valentin (Norway)

13:30-13:45 **Update on the English National Lynch syndrome Registry (National Disease Registration Service)**
Steven Hardy (United Kingdom)

13:45-14:00 **Lynch syndrome guideline harmonization - report on the work in progress**
Giulia Martina Cavestro (Italy)

14:00-14:15 **Immunotherapeutic options for patients with Lynch syndrome**
Andrea Cercek (USA)

14:15-15:15 **Fertility / Pregnancy**
Chairs: Neil Ryan (United Kingdom)
Denise Nebgen (USA)

14:15-14:30 **Management of colorectal cancer during pregnancy**
Jonas Ludvigsson (Sweden)

14:30-14:45 **Fertility preservation in gynaecological cancer**
Richard Anderson (United Kingdom)

14:45-15:00 **Fertility preservation in patients with gastrointestinal cancer syndromes**
Valeria Vanni (Italy)

15:00-15:15 **Surgery and quality of life**
José Gaston Guillem (USA)



Scientific Programme

Day 1 – Friday, September 27th

15:15-15:30 **Coffee break**

15:30-16:30 **Guidance from patient organizations**
Chairs: Nicola Reents (Germany)
Laura Monje-Garcia (United Kingdom)

15:30-15:40 **Living with Lynch: patient perspective**
Georgina Hoffmann (Germany/Canada)

15:40-15:50 **Examining Lynch syndrome Carriers' Perceptions of Care in the UK and Ireland**
BJ Olsen (Northern Ireland)

15:50-16:00 **Qualitative interview study: Exploring the opinions and attitudes towards nutritional advice from individuals with Lynch syndrome**
Isabelle Rennocks (United Kingdom)

16:00-16:10 **Who has the responsibility to inform relatives at risk of hereditary cancer? A population-based survey in Sweden**
Anna Rosén (Sweden)

16:10-16:20 **CMMRD – A Family Perspective**
Marisa I. Lopez-Messecaar (USA)

16:20-16:30 **Enhancing Lynch Syndrome management and services in the UK: The dual role of Lynch Syndrome UK in supporting patients and healthcare professionals**
Tracy Smith (United Kingdom)

Scientific Programme

Day 1 – Friday, September 27th

16:30-17:15 **Immunotherapy for colon and rectal cancer. Organ preservation for everyone?**
Chair: *Anna Martling (Sweden)*

Pro: *Julio Garcia-Aguilar (USA)*
Contra: *Dieter Hahnloser (Switzerland)*
Discussion with panel and auditorium

17:15-18:00 **Desmoid disease**
Chairs: *Elizabeth Half (Israel)*
David Liska (USA)

17:15-17:30 **Biological background and screening: Who and how should we screen for desmoids?**
Alona Zer (Israel)

17:30-17:45 **How and when to treat desmoid tumors: Medical treatment options for desmoid disease**
Silvia Stacchiotti (Italy)

17:45-18:00 **Surgical options for treatment of desmoid tumors**
Yann Parc (France)

18:00-18:30 **Keynote lecture I**
Chair: *Julian Sampson (United Kingdom)*

Targeting the Gut Microbiome for Cancer prevention and treatment
Phil Quirke (United Kingdom)

FTRD[®]

Endoscopic Full Thickness Resection

Closing the gap
between endoscopy and surgery

Decisive clinical difference in endoluminal surgery

FTRD[®] removes non-lifting and other complex GI lesions that were subject to surgery before.

The multicentric Wall Resect trial with a technical success rate of 89.5%¹ demonstrates that a variety of difficult to resect lesions, such as adenomas with non-lifting sign or subepithelial tumors, can be resected effectively. FTRD[®] thus enhances the spectrum of resection techniques and helps to avoid surgery.

FTRD[®] achieves high rates of complete resection where superficial removal techniques have their limitations.

Full thickness samples collected with FTRD[®] improve histological diagnosis. An R0 resection rate in 1178 cases from 65 centers of the German colonic FTRD[®] registry of 80.0%² substantiates the efficacy of FTRD[®] in clinical routine.

¹ Schmidt A, Beyna T, Schumacher B, Meining A, Richter-Schrag HJ, Messmann H, et al. Colonoscopic full-thickness resection using an over-the-scope device: a prospective multicentre study in various indications. Gut 2018 Jul;67(7):1280-1289.
² Meier B, Stritzke B, Kuellmer A, et al. Efficacy and safety of endoscopic full-thickness resection in the colorectum: Results from the German colonic FTRD registry. Am J Gastroenterol 2020; 115(12):1998-2006.



Scientific Programme

Day 2 – Saturday, September 28th

- 09:00-10:00 **Y-EHTG**
Chairs: Saskia Haupt (Germany)
Naim Abu-Freha (Israel)
- 09:00-09:10 **Y-EHTG – who we are and what we do**
Saskia Haupt (Germany)
- 09:10-09:40 **Dragons' Den – update on ongoing projects**
Sanne Bajwa-ten Broeke (The Netherlands)
Neil Ryan (United Kingdom)
Caroline Kahn (Denmark)
- 09:40-10:00 **Pitch new studies and projects of Y-EHTG members**
Predicting the unpredictable: using machine learning models to classify non-coding variants in the MMR genes
Carlos Urzua Traslavina (The Netherlands)

- 10:00-12:00 **4 parallel Working Groups**
- WG 1 Polyposis**
Chairs: Dan Buchanan (Australia)
Stefan Aretz (Germany)
Gloria Zaffaroni (Germany/Italy)
- WG 2 Carcinogenic mechanisms and pathways / early onset cancers / novel associations**
Chairs: Aysel Ahadova (Germany)
Julian Sampson (United Kingdom)
- WG 3 Genetics Counselling & Management (incl. Lab diagnosis, RNA seq, MMR variant interpretation)**
Chairs: Kelly Kohut (United Kingdom)
Fiona Laloo (United Kingdom)
- WG 4 Extra-colonic cancers in hereditary tumour syndroms**
Chairs: Neil Ryan (United Kingdom)
Christina Therkildsen (Denmark)

Scientific Programme

Day 2 – Saturday, September 28th

- 10:00-12:00 **WG 1 Polyposis**
Chairs: Dan Buchanan (Australia)
Stefan Aretz (Germany)
Gloria Zaffaroni (Germany/Italy)
- 10:00-10:12 **Different orders of events lead to colorectal cancer in familial adenomatous polyposis and inherited MSI cancers: implications for screening.**
Pål Møller (Norway)
- 10:12-10:24 **Immune characterisation of adenomas in Familial Polyposis Syndrome patients**
Sion Roberts (United Kingdom)
- 10:24-10:36 **Molecular and clinical differences between constitutional and somatic POLE and POLD1 exonuclease domain pathogenic variants in cancer**
Julen Viana-Errasti (Spain)
- 10:36-10:48 **The Role of Ferroptosis in Sporadic and Familial Intestinal Cancers**
Imogen Bennett (United Kingdom)
- 10:48-11:00 **Clinical phenotype, diagnostic route and unique presentations of PTEN Hamartoma Tumor Syndrome**
Einat Ritter (Israel)
- 11:00-11:12 **Identifying APC mosaicism in unexplained adenomatous polyposis: paving the way for the new susceptibility gene discovery**
Eric Joo (Australia)
- 11:12-11:24 **PIGA mutations and glycosylphosphatidylinositol anchor dysregulation in polyposis-associated duodenal tumorigenesis**
Laura Thomas (United Kingdom)
- 11:24-11:36 **Extended family with an inherited pathogenic variant in POLD1 provides strong evidence for recessive effect of polymerase delta proofreading deficiency in human cells**
Laura Valle (Spain)

Scientific Programme

Day 2 – Saturday, September 28th

- 10:00-12:00 **WG 2 Carcinogenic mechanisms and pathways / early onset cancers / novel associations**
*Chairs: Aysel Ahadova (Germany)
 Julian Sampson (United Kingdom)*
- 10:00-10:12 **Systemic FSP-specific T cell responses as predictive biomarker for immune checkpoint blockade therapy response in patients with microsatellite-unstable cancers?**
Lena Bohaumilitzky (Germany)
- 10:12-10:24 **Risk stratification of colorectal cancer using a combined effect of polygenic risk score and mismatch repair genes for Norwegian cohort**
Bayran Akdeniz (Norway)
- 10:24-10:36 **Prevalence of unexplained mismatch repair deficiency in colorectal cancer diagnosed at a tertiary cancer referral centre**
Lauren O'Connell (Ireland)
- 10:36-10:48 **Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation (Lynch syndrome and sporadic)**
Hugo Montemont (France/Germany)
- 10:48-11:00 **HLA genotype as a colorectal cancer risk modifier in Lynch syndrome**
Aaron Meyers (Australia)
- 11:00-11:12 **Tumor occurrence during follow up of 93 patients with Lynch syndrome treated with immune-check point inhibitor for metastatic digestive cancer between 2015 and 2024.**
Antoine Dardenne (France)
- 11:12-11:24 **Artificial intelligence-based tools for molecular subtype classification of colorectal carcinomas**
Julius Krauch (Germany)

Scientific Programme

Day 2 – Saturday, September 28th

- 11:24-11:36 **Aetiological insights into early-onset colorectal cancer and adenoma tumourigenesis through genomic tumour mutational signature profiling**
Daniel Buchanan (Australia)
- 11:36-11:48 **Diet and early-onset colorectal cancer: Validation of a novel ad hoc designed food frequency questionnaire**
Marta Puzzono (Italy)
- 11:48-12:00 **Constitutional epimutations in LTBP4 and in BRCA1 as drivers of early-onset colorectal cancer**
Mariona Terradas (Spain)
- 10:00-12:00 **WG 3 Genetics Counselling & Management (incl. Lab diagnosis, RNA seq, MMR variant interpretation)**
*Chairs: Kelly Kohut (United Kingdom)
 Fiona Laloo (United Kingdom)*
- 10:00-10:12 **A novel low cost amplicon based multiplex microsatellite instability assay with 22 driver BRAF/RAS mutations deployed across 3 million population allows discontinuation of routine colorectal cancer immunohistochemistry and enhanced Lynch syndrome detection.**
Richard Gallon (United Kingdom)
- 10:12-10:24 **The new English National Bowel Cancer Screening Programme (BCSP) for Lynch syndrome**
Kevin Monahan (United Kingdom)
- 10:24-10:36 **Interim outcomes from the NHS England Lynch syndrome Transformation Project: Finding the Missing 95%**
Kevin Monahan (United Kingdom)
- 10:36-10:48 **Is less really enough? Extent of colorectal cancer resection in Lynch syndrome**
Robert Hüneburg (Germany)

Scientific Programme

Day 2 – Saturday, September 28th

- 10:48-11:00 **Unmasking hidden genetic risks by comprehensive genetic testing of cancer patients**
Henriett Butz (Hungary)
- 11:00-11:12 **Mutational spectrum of Lynch syndrome in the Mid-South of Israel**
Rakefet Chen-Shtoyerman (Israel)
- 11:12-11:24 **ConEpiMut-DB: an international database to improve constitutional MLH1 epimutation diagnosis and research**
Paula Climent-Cantó (Spain)
- 11:24-11:36 **The Family Gene Kit: A tool to help families communicate and understand hereditary cancer**
Caroline Leek (United Kingdom)
- 11:36-11:48 **Introduction of a Mismatch Repair Deficiency Investigative Pathway to standardise the extent of testing in a tertiary cancer referral centre**
Rachel Clarke (Ireland)

10:00-12:00 **WG 4 Extra-colonic cancers in hereditary tumour syndroms**
*Chairs: Neil Ryan (United Kingdom)
Christina Therkildsen (Denmark)*

- 10:00-10:12 **An audit of current endometrial cancer mismatch repair testing and onward genetic referral in the United Kingdom and Republic of Ireland between March 2022 to March 2023.**
Neil Ryan (United Kingdom)
- 10:12-10:24 **Evaluation of upper gastrointestinal tract surveillance in individuals with Lynch syndrome (EARLY) – an international, multicenter registry**
Katrin van Beekum (Germany)
- 10:24-10:36 **Germline pathogenic variants in patients with pancreatic cancers according to family and personal history of cancer**
Elena Vida (Spain)

Scientific Programme

Day 2 – Saturday, September 28th

- 10:36-10:48 **Mutations in the ATRIP gene predispose to breast cancer**
Cezary Cybulski (Poland)
- 10:48-11:00 **A new gangster in town – A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma, Various Solid Malignancies and High Tumor Burden**
Yael Goldberg (Israel)
- 11:00-11:12 **SELINA – all-cause mortality and cancer risk after optimization of selenium and arsenic blood levels with inherited predispositions to breast cancer**
Jan Lubinski (Poland)
- 11:12-11:24 **Blood lead, molybdenum, zinc and iodine levels as a marker of cancers risk in BRCA1 carriers.**
Milena Matuszczak (Poland)
- 11:24-11:36 **MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations**
Jacek Gronwald (Poland)

12:00- 12:30 Lunch break

12:30-13:15 **My most challenging/interesting case**
*Chairs: Giulia Martina Cavestro (Italy)
Laura Valle (Spain)*

- 12:30-12:45 **Case 1
Catching the missing heritability in Lynch syndrome: the role of whole genome sequencing**
Vince Kornél Grolmusz (Hungary)
- 12:45-13:00 **Case 2
Early-onset hyperplastic polyposis and colon cancer with unexplained cause and clonal spread**
Esther Schamschula (Austria)
- 13:00-13:15 **Case 3
Metastatic Colorectal Cancer in Pregnancy: A Case Report**
Florian Scholz (Germany)

Scientific Programme

Day 2 – Saturday, September 28th

- 13:15-14:15 **Prevention Update**
Chairs: Elke Holinski-Feder (Germany)
Finlay Macrae (Australia)
- 13:15-13:35 **The MESACapp Study – an update on chemo-prevention for colorectal cancer with mesalamine**
Ann-Sofie Backman (Sweden)
- 13:35-13:55 **Risks and benefit of aspirin in prevention of hereditary colorectal cancer**
Andrew T. Chan (USA)
- 13:55-14:15 **Immune prevention in Lynch syndrome**
Matthias Kloor (Germany)
- 14:15-14:45 **Keynote lecture II**
Chair: John Burn (United Kingdom)
- The promise of liquid biopsy to reduce the burden of cancer**
Harpal Kumar (United Kingdom)
- 14:45-15:00 **Coffee break**
- 15:00-16:30 **EHTG-N Nursing Group**
Chairs: Laura Monje-Garcia (United Kingdom)
Mechelle Loughrey (Ireland)
Celia Diez de los Rios (Spain)
- 15:00-15:15 **A global collaboration to integrate genomics into nursing practice: The Global Genomics Nursing Alliance (G2NA)**
Kathleen Calzone (USA)

Scientific Programme

Day 2 – Saturday, September 28th

- 15:15-15:30 **Innovating Research to Demonstrate Nursing Sensitive Outcome Indicators**
Mary Ryder, Ireland
- 15:30-15:40 **Cancer nurses' role in risk reduction strategies with people with hereditary cancer syndromes: the importance of addressing health beliefs and lifestyle behaviors**
Celia Diez de los Rios (Spain)
- 15:40-15:50 **From diagnosis of colorectal cancer to diagnosis of Lynch syndrome at a tertiary cancer referral center – an Advanced Nurse Practitioner led mainstreaming model**
Mechelle Loughrey (Ireland)
- 15:50-16:00 **"It's a lifetime of worry" – making sense of uncertainty in Lynch syndrome: an interpretative phenomenological analysis**
Zanna Karsan (United Kingdom)
- 16:00-16:10 **Lynch syndrome surveillance: outcomes from a new regional tertiary center hub**
Helen Francis (United Kingdom)
- 16:10-16:20 **Nurse education to support Lynch syndrome genetic testing aligned with a national competency framework**
Karen Westaway (United Kingdom)
- 16:20-16:30 **Advancing inherited colorectal cancer research and services through comprehensive patient and public involvement: a real-life application from the PSYLIVED project**
Laura Monje-Garcia (United Kingdom)
- 16:30 **Meeting summary and closing remarks**
Gabriela Möslein (Germany)
Toni Seppälä (Finland)
- Invitation to 9th EHTG Meeting Heidelberg, 19.-21.09.2025**
Aysel Ahadova (Germany)

Faculty

Abu-Freha, Naim p 10	Soroka University Medical Center, Beer Sheva, Israel
Ahadova, Aysel p 12, 17	Heidelberg University Hospital, Heidelberg, Germany
Akdeniz, Bayram p 12	Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
Anderson, Richard p 6	University of Edinburgh, Edinburgh, United Kingdom
Aretz, Stefan p 11	Bonn University Hospital, Bonn, Germany
Backman, Ann-Sofie p 16	Karolinska Institute, Stockholm, Sweden
Bajwa-ten Broeke, Sanne p 10	University Medical Center Groningen, Groningen, The Netherlands
Bennett, Imogen p 11	Swansea University, Institute of Life Science 1 Swansea, United Kingdom
Bohaumilitzky, Lena p 12	Heidelberg University Hospital, Department of Applied Tumor Biology Heidelberg, Germany
Buchanan, Dan p 11, 13	University of Melbourne, Melbourne, Australia
Burn, Sir John p 6, 16	Newcastle University, Newcastle upon Tyne, United Kingdom
Butz, Henriett p 14	National Institute of Oncology Department of Molecular Genetics Budapest, Hungary
Calzone, Kathleen p 16	National Cancer Institute Bethesda, MD, USA
Cavestro, Giulia Martina p 6, 15	IRCCS San Raffaele Scientific Institute, Milan, Italy

Faculty

Cercek, Andrea p 6	Memorial Sloan Kettering Cancer Center, New York, NY, USA
Chan, Andrew T. p 16	Massachusetts General Hospital, Boston, MA, USA
Chen-Shtoyerman, Rakefet p 14	Ariel University, The Adelson School of Medicine and the Department of Molecular Biology Ariel, Israel
Clarke, Rachel p 14	St Vincent's University Hospital, Dublin, Ireland.
Climent-Cantó, Paula p 14	Catalan Institute of Oncology IDIBELL Hereditary Cancer Programme, L'Hospitalet de Llobregat, Spain
Cybulski, Cezary p 15	Pomeranian Medical University Department of Genetics and Pathology Szczecin, Poland
Dardenne, Antoine p 12	Cochin. AP-HP, Service de gastroentérologie et d'oncologie digestive Paris, France
Diez de los Rios, Celia p 16, 17	Barcelona University, Faculty of Nursing, Bellvitge Campus Barcelona, Spain
Dominguez-Valentin, Mev p 6	Oslo University Hospital, Oslo, Norway
Fernandez-Ortega, Paz p 17	Catalan Institute of Oncology IDIBELL Nursing Research L'Hospitalet de Llobregat, Spain
Francis, Helen p 17	ULCH London, United Kingdom
Gallon, Richard p 13	Newcastle University, Newcastle upon Tyne, United Kingdom



Faculty

Garcia-Aguilar, Julio
p 8

Memorial Sloan Kettering Cancer Center,
New York, NY, USA

Goldberg, Yael
p 15

Rabin Medical Center – Beilinson Hospital
Recanati Genetics Institute
Petah Tikva, Israel

Grolmusz, Vince Kornél
p 15

National Institute of Oncology
Budapest, Hungary

Gronwald, Jacek
p 15

Pomeranian Medical University,
Department of Genetics and Pathology
Szczecin, Poland

Guillem, José Gaston
p 6

UNC, Div. of Gastrointestinal Surgery,
Chapel Hill, NY, USA

Hahnloser, Dieter
p 8

Lausanne University Hospital,
Lausanne, Switzerland

Half, Elizabeth
p 8

Rambam Health Care Campus
Haifa, Israel

Hardy, Steven
p 6

NHS England,
United Kingdom

Haupt, Saskia
p 10

Heidelberg University Hospital
Heidelberg, Germany

Hoffmann, Georgina
p 7

SemiColon Germany
Schorndorf, Germany

Holinski-Feder, Elke
p 16

MGZ Medizinisches Genetisches Zentrum
München, Germany

Hüneburg, Robert
p 13

University Hospital Bonn,
Department of Internal Medicine I
Bonn, Germany

Joo, Eric
p 11

University of Melbourne
Melbourne, Australia

Faculty

Kahn, Caroline
p 10

The Danisch HNPCC Register and
The Colorectal Cancer Reserach Unit,
Copenhagen University Hospital
Hvidovre, Denmark

Karsan, Zanna
p 17

St George's University Hospitals
NHS Foundation Trust
London, United Kingdom

Kloor, Matthias
p 16

Heidelberg University Hospital,
Heidelberg, Germany

Kohut, Kelly
p 13

St. George's University Hospitals /
NHS Foundation Trust
London, United Kingdom

Krauch, Julius
p 12

Heidelberg University Hospital
Department of Applied Tumor Biology
Heidelberg, Germany

Kumar, Sir Harpal
p 16

GRAIL Inc.,
London, United Kingdom

Lallo, Fiona
p 13

Manchester Center for Genomic Medicine,
Manchester, United Kingdom

Leek, Caroline
p 14

Fruit Fly Collective
London, United Kingdom

Liska, David
p 8

Case Western Reserve University
Cleveland, Ohio, USA

Lopez-Messeccar, Marisa I.,
p. 7

CMMRD/BMMRD Awareness Group,
California, USA

Loughrey, Mechelle
p 16, 17

St. Vincent's University Hospital
Dublin, Ireland

Lubinski, Jan
p 15

Pomeranian Medical University
Department of Genetics and Pathology
Szczecin, Poland

Faculty

Ludvigsson, Jonas p 6	Karolinska Institute, Stockholm, Sweden
Macrae, Finlay p 16	Royal Melbourne Hospital Melbourne, Australia
Martling, Anna p 8	Karolinska Institute, Stockholm, Sweden
Matuszczak, Milena p 15	Pomeranian Medical University Department of Genetics and Pathology Szczecin, Poland
Meyers, Aaron p 12	University of Melbourne Centre for Cancer Research Melbourne, Australia
Møller, Pål p 11	The Norwegian Radium Hospital Department of Tumour Biology Oslo, Norway
Monahan, Kevin p 6, 13	Imperial College London, United Kingdom
Monje-Garcia, Laura p 16, 17	Imperial College London London, United Kingdom
Montemont, Hugo p 12	Sorbonne University, Hôpital Saint-Antoine, APHP, Paris, France/Germany
Möslein, Gabriela p 17	Bethesda University Hospital Duisburg, Germany
Nebgen, Denise p 6	University of Texas MD, Anderson Cancer Center, Houston, USA
O'Connell, Lauren p 12	St Vincent's University Hospital, Dublin, Ireland
Olsen, BJ p 7	Royal Victoria Hospital Belfast health and social care Trust Belfast, Northern Ireland



Faculty

Parc, Yann p 8	Sorbonne University, Hôpital Saint-Antoine, APHP, Paris, France
Puzzono, Marta p 13	IRCCS San Raffaele Scientific Institute Gastroenterology and Gastrointestinal Endoscopy Unit Milan, Italy
Quirke, Phil p 8	University of Leeds, Leeds, United Kingdom
Reents, Nicola p 7	SemiColon Germany Mönchengladbach, Germany
Rennocks, Isabelle p 7	Cardiff University School of Medicine Cardiff, United Kingdom
Ritter, Einat p 11	Tel Aviv Sourasky Medical Center Department of Gastroenterology Tel Aviv, Israel
Roberts, Sion p 11	Swansea University Institute of Life Science 1 Swansea, United Kingdom
Rosén, Anna p 7	Umeå University Department of Diagnostics and Intervention, Oncology Umeå, Sweden
Ryan, Neil p 6, 10, 14	University of Edinburgh, Edinburgh, United Kingdom
Ryder, Mary p 17	University College Dublin Dublin, Ireland
Sampson, Julian p 8, 12	Cardiff University, Cardiff, United Kingdom
Schamschula, Esther p 15	Medical University of Innsbruck Department of Human Genetics Innsbruck, Austria

Faculty

Scholz, Florian
p 15

Ludwig-Maximilians-University
Department of General, Visceral and
Transplantation Surgery
Munich, Germany

Seppälä, Toni
p 17

University of Helsinki
Department of Surgery
Helsinki, Finland

Smith, Tracy
p 7

Lynch Syndrome UK Charity
Carnforth, United Kingdom

Stacchiotti, Silvia
p 8

Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy

Terradas, Mariona
p 13

Catalan Institute of Oncology IDIBELL
Hereditary Cancer Programme
L'Hospitalet de Llobregat, Spain

Therkildsen, Christina
p 14

Copenhagen University Hospital,
Hvidovre, Denmark

Thomas, Laura
p 11

Cardiff University
School of Medicine
Cardiff, United Kingdom

Urzua Traslavina, Carlos
p.10

University Medical Center Groningen
Groningen, The Netherlands

Valle, Laura
p 11, 15

Catalan Institute of Oncology IDIBELL
Hereditary Cancer Programme
L'Hospitalet de Llobregat, Spain

van Beekum, Katrin
p 14

University Hospital Bonn
National Center for Hereditary Tumor Syndromes
Bonn, Germany

Vanni, Valeria
p 6

SMC – Sunmedical Center S.r.l.,
Milan, Italy

Viana-Errasti, Julen
p 11

Catalan Institute of Oncology IDIBELL
Hereditary Cancer Programme
L'Hospitalet de Llobregat, Spain

Faculty

Vida, Elena
p 14

Hospital Universitario Ramón y Cajal
Madrid, Spain

Westaway, Karen
p 17

West Yorkshire & Harrogate Cancer Alliance
Sheffield, United Kingdom

Winship, Ingrid
p 6

University of Melbourne
Melbourne, Australia

Zaffaroni, Gloria
p 11

Evangelic Bethesda Hospital,
Duisburg, Germany/Italy

Zer, Alona
p 8

Rambam Medical Center,
Haifa, Israel

Sponsors



www.ovesco.com

1.000 EUR



www.newcastle-hospitals.nhs.uk

1.000 EUR

Imprint

Responsible in accordance with press law:

Prof. Dr. med. Gabriela Moeslein
 Evangelisches Bethesda Krankenhaus
 Zentrum für Hereditäre Tumorerkrankungen
 47053 Duisburg
gabriela.moeslein@ehtg.org

Organisation:

EHTG secretariat and
 MCE – Medical Congresses & Events e.K.:
 Gabriele Sponholz, gs007@ehtg.org / gs@mce.info



9TH ANNUAL MEETING
Heidelberg • 2025

SAVE THE DATE

**9th Meeting of the
European Hereditary Tumour Group (EHTG)**

Friday, Sept 19th – Sunday, Sept 21th, 2025

Heidelberg, Germany

We would like to announce the 2025 Meeting which will take place in Heidelberg, Germany. Details to follow soon on our website: www.ehtg.org

**10th Meeting of the
European Hereditary Tumour Group (EHTG)**

September 2026

To be announced

11th Meeting 2027:

Call for venue application 2027 will be announced early 2025.

